← Eichor
Study identifier: NCT06767332 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial

Condition: Familial Melanoma · Fear of Cancer Recurrence · Eye Movement Desensitization and Reprocessing  ·  Sponsor: Leiden University Medical Center

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

High fear of cancer recurrence (FCR) impacts patient's quality of life (QoL) and is prevalent among patients with familial melanoma. The main objective is to investigate whether EMDR is effective in treating high FCR in patients with familial melanoma. The study design is a non-blinded, randomized waiting-list controlled trial. Patients aged 18 years or older with familial melanoma can be included. Patients with high FCR will receive a maximum of 4, 90 minutes, EMDR-sessions. The main study parameter is the decrease and level of FCR measured with the Cancer Worry Scale (CWS). The secondary study parameter is quality of life, measured with the EORTC.

This description comes directly from the study's public registry record.

Talk to the study team

Sanne K. de Bie, Drs.  ·  0031 71 526 3615  ·  s.k.de_bie@lumc.nl

Chris Hinnen, Dr.  ·  0031 71 526 3615  ·  s.c.h.hinnen@lumc.nl

Always discuss trial participation with your own doctor first.

Locations (2)

Leiden University Medical CenterLeiden, South Holland, NetherlandsRecruiting
Leiden University Medical CentreLeiden, South Holland, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06767332